secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2023-12-26T23:59:59+00:00
Accession:  0001193125-23-303051
Event type: m_and_a
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Graphite Bio clears HSR waiting period for merger with Lenz Therapeutics on Dec. 21
--------------------------------------------------------------------------------

- HSR waiting period under Hart-Scott-Rodino Act expired at 11:59 p.m. ET on December 21, 2023.
- Merger with Lenz Therapeutics, previously announced Nov. 14, 2023, remains subject to stockholder approval and other conditions.
- Closing will result in Lenz becoming a wholly owned subsidiary of Graphite; combined company intends to list on Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000119312523303051/0001193125-23-303051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000119312523303051/d541575d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-303051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer